# Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

> **NCT06409429** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 146 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Nimotuzumab
- **DRUG:** GX
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06409429
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2027-05-30
- **Final completion:** 2027-05-30
- **Target enrollment:** 146 (ESTIMATED)
- **Last updated:** 2024-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06409429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06409429, "Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06409429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*